BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst (Nasdaq: BCRX) granted inducement restricted stock units covering an aggregate of 30,700 shares to three newly hired employees, effective November 3, 2025.
The awards were approved by the compensation committee as inducements under Nasdaq Listing Rule 5635(c)(4) and are governed by the company’s Inducement Equity Incentive Plan and individual RSU agreements. The RSUs vest in four equal annual installments beginning on the one‑year anniversary of the grant, each installment subject to the employee’s continued service.
BioCryst (Nasdaq: BCRX) ha concesso unità di azioni con restrizioni di incentivo (RSU) per un importo complessivo di 30.700 azioni a tre neoassunti dipendenti, con effetto a partire dal 3 novembre 2025.
Le assegnazioni sono state approvate dal comitato di compensazione come incentivi ai sensi della Regola di quotazione Nasdaq 5635(c)(4) e sono disciplinate dal piano aziendale Inducement Equity Incentive Plan e dagli accordi RSU individuali. Le RSU vestono in quattro rate annuali uguali, a partire dall'anniversario di un anno della concessione, con ciascuna rata soggetta al continuo servizio del dipendente.
BioCryst (Nasdaq: BCRX) concedió unidades de acciones con restricción de incentivo que cubren un total de 30.700 acciones a tres empleados recién contratados, con efecto a partir del 3 de noviembre de 2025.
Los premios fueron aprobados por el comité de compensación como incentivos conforme a la Regla 5635(c)(4) de listado de Nasdaq y se rigen por el plan de incentivos de capital por inducción de la empresa (Inducement Equity Incentive Plan) y por los acuerdos individuales de RSU. Las RSUs se consolidan en cuatro cuotas anuales iguales, a partir del aniversario de un año desde la concesión, y cada cuota está sujeta al mantenimiento del servicio por parte del empleado.
BioCryst (나스닥: BCRX)은 신입 직원 3명에게 총 30,700주의 유인 유가 주식 보상을 부여했으며, 발효일은 2025년 11월 3일입니다.
이 보상은 보상위원회가 나스닥 상장 규칙 5635(c)(4)에 따른 유인으로 승인했으며, 회사의 Inducement Equity Incentive Plan 및 개별 RSU 계약에 따라 관리됩니다. 이 RSU는 네 번의 동일한 연간 분할로 vest되며, 각 분할은 부여일 1주년부터 시작되며, 각 분할은 피고용인의 지속적인 근무에 달려 있습니다.
BioCryst (Nasdaq: BCRX) a accordé des unités d’actions restreintes d’induction couvrant un total de 30 700 actions à trois nouveaux employés embauchés, avec effet au 3 novembre 2025.
Les récompenses ont été approuvées par le comité de rémunération en tant qu’inducements selon la Règle 5635(c)(4) de la cotation Nasdaq et sont régies par le plan d’incitation d’équité Inducement Equity Incentive Plan et les accords RSU individuels. Les RSU s’acquièrent en quatre versements annuels égaux, à compter de l’anniversaire d’un an de la subvention, chaque versement étant soumis à la poursuite du service par l’employé.
BioCryst (Nasdaq: BCRX) gewährt Anreiz-aktienbasierte Restricted Stock Units in Höhe insgesamt 30.700 Aktien an drei neu eingestellte Mitarbeiter, mit Wirkung zum 3. November 2025.
Die Zuteilungen wurden vom Vergütungsausschuss als Anreize gemäß Nasdaq Listing Rule 5635(c)(4) genehmigt und unterliegen dem unternehmensweiten Inducement Equity Incentive Plan sowie individuellen RSU-Vereinbarungen. Die RSUs vesten in vier gleichen Jahresraten, beginnend am ersten Jahrestag der Gewährung, wobei jede Rate von der fortgesetzten Beschäftigung des Mitarbeiters abhängt.
BioCryst (ناسداك: BCRX) منحت وحدات أسهم مقيدة كحوافز تغطي إجمالياً 30,700 سهماً لثلاثة موظفين جدد، وتصبح سارية المفعول في 3 نوفمبر 2025.
تمت الموافقة على الجوائز من قبل لجنة التعويضات كمحفّزات وفق قاعدة إدراج ناسداك 5635(c)(4) وهي تخضع لخطة تحفيز الأسهم للمحفّز Inducement Equity Incentive Plan وللاتفاقيات الفردية لـ RSU. تتكون RSUs من أربعة أقساط سنوية متساوية تبدأ في ذكرى السنة الأولى من المنح، وتخضع كل قسط لاستمرار خدمة الموظف.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst common stock. The RSUs were granted as of November 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
What did BioCryst (BCRX) announce on November 5, 2025 about new-hire equity?
How do the BioCryst (BCRX) RSUs vest and when does vesting begin?
Under what rule were the BioCryst (BCRX) RSUs granted as inducements?
Are the BioCryst (BCRX) RSUs subject to a plan or agreement?
How many employees received inducement RSUs in the BioCryst (BCRX) announcement?
